Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2825 in diffuse large B cell lymphoma
NCT06829771Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2025
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tqb2825 in diffuse large B-cell lymphoma (DLBCL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2025; status: recruiting.
02
Drugs
tqb2825
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06829771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06829771.